1. Taiwan Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Gongwin Biopharm Holdings Co., Ltd.

Gongwin Biopharm Holdings Co., Ltd.

TTPEX:6617
117.50
TWD
+1.50
(+1.29%)
-1.45EPS
8.44BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
0.01
- -
- -
0.01
0.01
0.01
0.17
0.27
0.3
0.35
Basic EPS, GAAP
-0.21
-0.17
-0.35
-1.03
-1.23
-1.06
-1.05
-0.88
-1.1
-2.29
-0.81
-0.68
-0.92
-1.35
Free Cash Flow per Basic Share
-0.3
-0.07
-0.61
-1.08
-1.08
-1.6
-1.05
-1.11
-0.86
-2.14
-0.98
-2.43
-1.12
-1.63
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.19
0.04
4.95
6.7
5.38
7.22
6.23
9.89
8.73
12.31
11.61
24.64
20.64
19.21
Tangible Book Value per Share
0.19
0.04
4.94
6.69
5.38
7.22
6.23
9.89
8.73
12.31
11.61
24.64
20.63
19.2
Basic Weighted Avg Shares
91
91
91
99
101
105
104
106
111
111
113
121
123
122
Sales/Revenue/Turnover
- -
- -
- -
- -
1
- -
- -
1
1
1
19
32
36
42
Operating Margin (%)
- -
- -
- -
-114,986.02
-13,110.73
-199,758.06
-51,944.76
-14,089.56
-10,570.95
-22,806.74
-704.87
-487.35
-573.26
-574.67
Depreciation Expense
- -
2
3
4
5
7
12
13
13
13
13
12
12
12
Net Income, GAAP
-19
-16
-32
-102
-124
-111
-110
-93
-122
-254
-92
-83
-114
-165
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-109,589.25
-11,755.84
-178,624.19
-44,283.87
-11,173.11
-10,637.01
-22,238.76
-486.58
-257.64
-313.14
-389.63
Working Capital
39
5
480
669
503
689
608
1,005
765
1,146
993
2,251
1,688
1,511
LT Debt
- -
- -
3
- -
18
18
- -
2
- -
2
- -
13
9
8
Total Equity
38
25
505
698
561
781
697
1,118
987
1,373
1,312
3,100
2,518
2,326
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-134.31
-12.85
-17.44
-20.12
-16.79
-15.29
-10.58
-11.78
-21.52
-6.8
-3.73
-4.05
-6.86

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
120
130
142
LT Borrowings
- -
- -
- -
LT Finance Leases
9
9
8
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
123
121
121
Market Capitalization
10,558
7,879
8,442

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,868
1,750
1,721
Cash, Cash Equivalents & STI
1,824
1,700
1,671
Accounts Receivable, Net
11
10
12
Inventories
1
5
5
Total Current Liabilities
180
190
210
Payables & Accruals
- -
- -
- -
ST Debt
120
130
142
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.79%
28.09%
-18.79%
Free Cash Flow
30.92%
37.78%
-52.92%
Net Income, GAAP
32.19%
20.77%
38.25%
Sales/Revenue/Turnover
- -
- -
13.75%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5
8
9
9
32
2025
8
9
12
8
36
2026
9
13
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.22
-0.22
-0.08
-0.17
-0.68
2025
-0.09
-0.16
-0.29
-0.39
-0.92
2026
-0.32
-0.35
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Mao Yuan Lin
Full Time Employees
20
Sector
Distribution services
Industry
Medical distributors
Address
No. 80, Jianguo North Road Taipei TP Taiwan 10491
IPO Date
Jun 18, 2024
Website
gongwinbiopharm.com
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Gongwin Biopharm Holdings Co., Ltd. (6617.TWO) is a Cayman Islands-incorporated, Taiwan-based clinical-stage biopharmaceutical company that develops novel anti-cancer drugs utilizing its proprietary MITTA (Minimally Invasive Targeted Tumor Ablation) technology, which involves intratumoral injection of para-toluenesulfonamide (PTS) for treating focal solid tumors with high selectivity for cancer cells and minimal damage to healthy tissue; core pipeline products include PTS302 (Purocenta®), approved by China's NMPA in 2023 and newly listed in the Chinese Pharmacopeia for severe malignant airway obstructions in non-small cell lung cancer following Phase III trials, PTS100 in Phase II for hepatocellular carcinoma, PTS-02 for tracheal adenoid cystic carcinoma (with U.S. orphan drug designation), PTS500 for malignant pleural effusion, and GWA-103 for canine melanoma (with field trials approved in Taiwan in 2022 and IND submitted in 2024); the company also pursues veterinary applications and conducts R&D in pharmaceutical testing, biotechnology services, and technology transfer across Taiwan, mainland China, and the U.S. Founded in 2014 with headquarters at No. 80, Jianguo North Road, Taipei, Taiwan, Gongwin operates GMP-certified R&D centers including its 2020-opened facility in New Taipei Industrial Park and maintains cooperative relationships with over 120 institutes in 15+ countries targeting human and companion animal oncology. Recent developments encompass its June 2024 initial public offering on the Taipei Exchange, participation in key 2025 events such as BIO Partnering at JPM Week, APCB Taipei, and ASCO presentations on PTS for malignant pleural effusions, alongside ongoing U.S. regulatory advancements stemming from 1994 PTS discovery and 2004 FDA IND approval, and expansion of canine neurotendinoma and melanoma programs with 2022 MUMS approvals.